1. Please check and comment entries here.
Table of Contents

    Topic review

    Lewy Body Dementias

    Subjects: Oncology
    View times: 5
    Submitted by: Angela Milán-Tomás


    Lewy body dementias (LBDs) consist of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), which are clinically similar syndromes that share neuropathological findings with widespread cortical Lewy body deposition, often with a variable degree of concomitant Alzheimer pathology. The objective of this article is to provide an overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD. Literature research was performed using the PubMed database, and the most pertinent articles were read and are discussed in this paper. The diagnostic criteria for DLB have recently been updated, with the addition of indicative and supportive biomarker information. The time interval of dementia onset relative to parkinsonism remains the major distinction between DLB and PDD, underpinning controversy about whether they are the same illness in a different spectrum of the disease or two separate neurodegenerative disorders. The treatment for LBD is only symptomatic, but the expected progression and prognosis differ between the two entities. Diagnosis in prodromal stages should be of the utmost importance, because implementing early treatment might change the course of the illness if disease-modifying therapies are developed in the future. Thus, the identification of novel biomarkers constitutes an area of active research, with a special focus on α-synuclein markers. 

    1. Introduction

    Lewy body dementia is an umbrella term that includes Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), which are two entities on a spectrum of Lewy body disease. The two disorders share many clinical and pathological features, including the deposition of widespread limbic and cortical Lewy bodies and Lewy neurites composed of aggregates of α-synuclein (α-syn) [1] and loss of midbrain dopamine cells and cholinergic neurons in the ventral forebrain nuclei [2].
    DLB is the second most common form of dementia after Alzheimer’s disease (AD). However, previous studies have shown a wide prevalence variation, probably due to DLB being underdiagnosed [3]. In a systematic review of twenty-two studies addressing the prevalence and incidence of DLB [4], DLB accounted for 3.2–7.1% of all dementia cases in the incidence studies, and the point and period prevalence estimates increased with age and ranged from 0.02 to 63.5 per 1000 persons. Nevertheless, these numbers probably underestimate the true prevalence and incidence of DLB because misdiagnosis as AD is common [3].
    In addition to the common motor manifestations of Parkinson’s disease (PD) (tremor, rigidity, akinesia), other non-motor manifestations, such as sensory abnormalities, autonomic dysfunction, and behavioral and cognitive changes, are common [5][6]. About 25% of patients newly diagnosed with PD fulfill the diagnosis of mild cognitive impairment (PD-MCI) [7][8]; at follow-up (mean follow-up 23.5 ± 10.3 months), 33.3% of the PD cognitively normal patients develop MCI and 4.8% convert to PDD, resulting in an incidence rate of 123.5/1000 per year (95% CI 70.3–202.2) [9]. Most individuals with PD have MCI or dementia with the progression of the disease [10][11][12], which occur in up to 83% of cases after 20 years of disease duration [13].
    The diagnosis of PDD and DLB is challenging because many clinical manifestations and additional findings in the examinations overlap. However, reaching an early and accurate diagnosis is critical to disentangle the heterogeneity of these two entities, and to develop proper and specific clinical trials of neuroprotective therapies, thus providing an early optimal treatment and a correct prognosis to patients and caregivers. The purpose of this article is to provide an overview of the main neuropathological findings, clinical features, current diagnostic criteria, principal biomarkers, and management of DLB and PDD.

    2. Current Diagnostic Criteria for Parkinson’s Disease Dementia and Lewy Body Dementia

    Table 1 shows the current diagnostic criteria for PDD and DLB. For the clinical diagnosis of both entities, dementia syndrome must always be present.
    Table 1. Criteria for the clinical diagnosis of probable and possible dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
    DLB 1 PDD 2
    Central features Essential for a diagnosis: Dementia, in early stages with memory impairment, may not necessarily occur but is usually evident with progression. Deficits in tests of attention, executive function, and visuoperceptual ability may be especially prominent and occur early. Core Features (I) Essential for a diagnosis (both must be present): Diagnosis of Parkinson disease according to Queen Square Brain Bank criteria and Dementia syndrome with impairment in more than one cognitive domain
    Core clinical features The first three typically occur early and may persist throughout the course:
    • Fluctuating cognition with pronounced variations in attention and alertness.
    • Recurrent visual hallucinations that are typically well formed and detailed.
    • REM sleep behavior disorder (may precede cognitive decline).
    Associated clinical features (II)
    • Typical profile of cognitive deficits (at least two of the four core cognitive domains): impaired attention (which may fluctuate), executive, and visuo-spatial functions, and impaired free recall memory, which usually improves with cueing.
    • The presence of at least one behavioral symptom (apathy, depressed or anxious mood, hallucinations, delusions, or excessive daytime sleepiness) supports the diagnosis of probable
    One or more spontaneous cardinal features of parkinsonism: bradykinesia, rest tremor, or rigidity.
      PDD; lack of behavioral symptoms, however, does not exclude the diagnosis
    Supportive clinical features Severe sensitivity to antipsychotic agents; postural instability; repeated falls; syncope or other transient episodes of unresponsiveness; severe autonomic dysfunction, e.g., constipation, orthostatic hypotension, urinary incontinence; hypersomnia; hyposmia; hallucinations in other modalities; systematized delusions; apathy, anxiety, and depression. None of the group (III) features present Features which do not exclude PDD, but make the diagnosis uncertain:
    • Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of dementia, e.g., presence of relevant vascular disease in imaging
    • Time interval between the development of motor and cognitive symptoms not known
    Indicative biomarkers
    • Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET.
    • Abnormal (low uptake) 123iodine-MIBG myocardial scintigraphy.
    • Polysomnographic confirmation of REM sleep without atonia.
    None of the group (IV) features present Features suggesting other conditions or diseases as cause of mental impairment, which, when present, make it impossible to reliably diagnose PDD: 1. Cognitive and behavioral symptoms appearing solely in the context of other conditions such as acute confusion due to (a.) systemic diseases or abnormalities (b.) drug intoxication
    2. Major Depression according to DSM IV
    Supportive biomarkers
    • Relative preservation of medial temporal lobe structures on CT/MRI scan.
    • Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity +/− the cingulate island sign on FDG-PET imaging.
    • Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range.
    or indicative biomarkers
    No supportive or indicative biomarkers are needed for the diagnosis of PDD as per Emre et al. (2007) diagnostic criteria.
    Diagnosis of
    Probable: (a) ≥2 core clinical features of DLB are present, with or without the presence of indicative biomarkers, OR (b). Only one core clinical feature is present, but with ≥1 indicative biomarkers. Probable DLB should not be diagnosed on the basis of biomarkers alone.
    Possible: (a). Only one core clinical feature of DLB is present, with no indicative biomarker evidence, OR (b). ≥1 indicative biomarkers is present but there are no core clinical features.
    Diagnosis of probable or possible
    Probable: (a) Core features: Both must be present; (b). Associated clinical features: Typical profile of cognitive deficits and the presence of at least one behavioral symptom (lack of behavioral symptoms, however, does not exclude the diagnosis); (c) None of the group III features present; (d) None of the group IV features present.
    Possible: (a) Core features: Both must be present (b). Associated clinical features: Atypical profile of cognitive impairment in one or more domains (e.g., fluent aphasia, or pure storage-failure type amnesia) and behavioral symptoms may or may not be present; OR (c) One or more of the group III features present, (d) None of the group IV features present

    3. Diagnostic Approach

    PD subjects who develop dementia do not need further complementary examinations as per the PDD diagnostic criteria [14] (see Figure 1). Like in DLB, a comprehensive neuropsychological evaluation including the assessment of specific cognitive domains (attention, memory, executive functions, language, construction, praxis, and visuospatial functions) is useful to assess the specific profile of cognitive impairment.
    Figure 1. Proposed algorithm for the diagnostic approach in Parkinson’s disease dementia. * Parkinson’s disease diagnosis must be present. a See Table 1 for the group III features. b See Table 1 for the group IV features.
    The diagnosis of DLB is based on the clinical history, physical evaluation, and neuropsychological assessment. When two core clinical features are present, the diagnosis of probable DLB is made, but in the case of only one core feature, the positivity of one or more indicative biomarkers (e.g., DAT-scan or 123IMBG) helps in the diagnosis of probable DLB.
    Moreover, for those patients in which dementia syndrome does not meet any of the core features of DLB, indicative biomarkers could be performed to establish the diagnosis of “possible” DLB or other neurodegenerative processes such as AD [15][16]. For those patients with atypical findings (e.g., a cognitive profile affecting memory rather than executive or visuospatial dysfunction), or for those patients with dementia in which only one of the core features of DLB is present, the use of functional imaging (e.g., DAT scans) or other indicative biomarkers may help in the diagnosis of probable DLB (see Figure 2). Supportive biomarkers such as FDG-PET, showing the typical “island sign,” or a brain MRI with relative preservation of medial temporal lobe structures, increase the certainty of a DLB diagnosis [17].
    Figure 2. Proposed algorithm for the diagnostic approach in Lewy body dementia. * Supportive biomarkers that help in the diagnostic evaluation but without clear diagnostic specificity. a The cingulate island sign is only identifiable in FDG-PET, not in SPECT. DLB, dementia with Lewy bodies; DAT; dopamine transporter; F-DOPA, Flurodopa PET; SPECT, single photon emission computed tomography; PET, positron emission tomography; MIBG, iodine-123 –metaiodobenzylguanidine; PSG, polysomnography; MRI, magnetic resonance imaging; FDG-PET, fluoro-deoxy-glucose PET; EEG, electroencephalogram.

    4. Behavioral and Neuropsychiatric Manifestations of Lewy Body Dementias

    Neuropsychiatric manifestations are common in LBD patients. Depression, anxiety, and apathy are frequent in PDD and DLB [18][19][20][21][22], and they are included as supportive and associated features of both entities (Table 1). They may share a similar substrate, with depression being one of the most studied non-cognitive psychiatric disorders in PD, occurring in up to 50% of PD patients at some point in the course of their illness [21]. Depression is also linked to cognitive impairment [23][24]. Moreover, premorbid depression has been shown to be significantly more common in PD patients than in those without a diagnosis of PD [6][25][26], preceding the motor symptoms and possibly dementia diagnosis of LBD [6][22]. Depression in DLB is also very frequent, with a prevalence of approximately 28% [27], and overall, depression in LBD is more frequent when compared to AD [28].
    Apathy, defined by reduced initiative and motivation, appears to be equally common in PDD and DLB, reported in 54% of PDD patients [29] and in 57% of DLB [30]. Moreover, apathy appears to be associated with more serious symptomatology in DLB and faster cognitive decline [31]. Regarding anxiety, comparisons of its prevalence in PDD and DLB are lacking [32], but appear to be worse in DLB compared to in AD [33].
    The psychosis spectrum in PD was recently reviewed [34] and includes minor experiences or hallucinations, such as passage and presence hallucinations or illusions in the early stages of PD [19], and well-formed complex recurring visual hallucinations with other modalities of hallucinations and delusions in later PD stages. The presence of cognitive impairment, depression, and dopaminergic use have been described as risk factors for hallucinations [35], and its phenomenology in PDD and DLB is very similar, with the majority of patients experiencing recurrent, complex visual hallucinations—seeing adults or small children, deceased family members, or small animals [1]. Visual hallucinations are usually more frequent and severe in DLB than in PDD (76% vs. 54%) [22], whereas auditory and other modalities of hallucinations are less prevalent in both entities [36][37]. Although hallucinations in PD may be triggered by the use of dopaminergic therapies, they can occur in drug-naïve PD patients [38]; however, they appear more often in DLB spontaneously [18].
    A study analyzed the utility of pareidolias, measured by the Pareidolia test, as a surrogate indicator of visual hallucinations in patients with DLB [39]. The authors found that pareidolic responses were observed more frequently in patients with DLB than AD or healthy controls, and were detected even in patients without visual hallucinations. Thus, they proposed that pareidolic responses could be a possible predictive marker of DLB. In other study including PD patients without dementia [40], authors found that the number of pareidolic illusions correlated with hypometabolism in the bilateral temporal, parietal, and occipital cortices, which may suggest that posterior cortical dysfunction could be a common neural substrate of pareidolia and visual hallucinations. However, the test has not been properly assessed in PDD, so its utility as a diagnostic tool is not known.
    In summary, although behavioral and neuropsychiatric symptoms are common in both PDD and DLB, most of the studies have shown that some of them, such as visual hallucinations and delusions, are more prevalent and severe in DLB compared to PDD [18][22]. Mood disturbances such as depression or apathy appear to be equally common in both disorders, but these are higher than in AD population. The use of questionnaires and other tools assessing neuropsychiatric symptoms in patients with LBD is relevant to obtain an adequate characterization of these manifestations and may help in the diagnosis.

    The entry is from 10.3390/bs11070094


    1. Harding, A.J.; Halliday, G.M. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001, 102, 355–363.
    2. Klein, J.C.; Eggers, C.; Kalbe, E.; Weisenbach, S.; Hohmann, C.; Vollmar, S.; Baudrexel, S.; Diederich, N.J.; Heiss, W.D.; Hilker, R. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74, 885–892.
    3. Zaccai, J.; McCracken, C.; Brayne, C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005, 34, 561–566.
    4. Hogan, D.B.; Fiest, K.M.; Roberts, J.I.; Maxwell, C.J.; Dykeman, J.; Pringsheim, T.; Steeves, T.; Smith, E.E.; Pearson, D.; Jetté, N. The prevalence and incidence of dementia with lewy bodies: A systematic review. Can. J. Neurol. Sci. 2016, 43, S83–S95.
    5. Pfeiffer, R.F. Non-motor symptoms in Parkinson’s disease. Park. Relat. Disord. 2016, 22, S119–S122.
    6. Rodriguez-Oroz, M.C.; Jahanshahi, M.; Krack, P.; Litvan, I.; Macias, R.; Bezard, E.; Obeso, J.A. Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms. Lancet Neurol. 2009, 8, 1128–1139.
    7. Litvan, I.; Goldman, J.G.; Tröster, A.I.; Schmand, B.A.; Weintraub, D.; Petersen, R.C.; Mollenhauer, B.; Adler, C.H.; Marder, K.; Williams-Gray, C.H.; et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 2012, 27, 349–356.
    8. Goldman, J.G.; Sieg, E. Cognitive impairment and dementia in Parkinson disease. Clin. Geriatr. Med. 2020, 36, 365–377.
    9. Nicoletti, A.; Luca, A.; Baschi, R.; Cicero, C.E.; Mostile, G.; Davì, M.; Pilati, L.; Restivo, V.; Zappia, M.; Monastero, R. Incidence of mild cognitive impairment and dementia in Parkinson’s disease: The Parkinson’s disease cognitive impairment study. Front. Aging Neurosci. 2019, 10, 1–12.
    10. Janvin, C.C.; Larsen, J.P.; Aarsland, D.; Hugdahl, K. Subtypes of mild cognitive impairment in Parkinson’s disease: Progression to dementia. Mov. Disord. 2006, 21, 1343–1349.
    11. Gasca-Salas, C.; Estanga, A.; Clavero, P.; Aguilar-Palacio, I.; González-Redondo, R.; Obeso, J.A.; Rodriguez-Oroz, M.C. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson’s disease. J. Parkinson’s Dis. 2014, 4, 677–686.
    12. Litvan, I.; Aarsland, D.; Adler, C.H.; Goldman, J.G.; Kulisevsky, J.; Mollenhauer, B.; Rodriguez-Oroz, M.C.; Tröster, A.I.; Weintraub, D. MDS task force on mild cognitive impairment in Parkinson’s disease: Critical review of PD-MCI. Mov. Disord. 2011, 26, 1814–1824.
    13. Hely, M.A.; Reid, W.G.J.; Adena, M.A.; Halliday, G.M.; Morris, J.G.L. The Sydney Multicenter Study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov. Disord. 2008, 23, 837–844.
    14. Emre, M.; Aarsland, D.; Brown, R.; Burn, D.J.; Duyckaerts, C.; Mizuno, Y.; Broe, G.A.; Cummings, J.; Dickson, D.W.; Gauthier, S.; et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 2007, 22, 1689–1707.
    15. Thomas, A.J.; Donaghy, P.; Roberts, G.; Colloby, S.J.; Barnett, N.A.; Petrides, G.; Lloyd, J.; Olsen, K.; Taylor, J.P.; McKeith, I.; et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol. Med. 2019, 49, 396–402.
    16. Yoshita, M.; Taki, J.; Yamada, M. A clinical role for [123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 2001, 71, 583–588.
    17. Mckeith, I.G.; Sci, M.; Boeve, B.F.; Dickson, D.W.; Halliday, G.; Taylor, J.-P.; Psych, M.; Weintraub, D.; Aarsland, D.; Galvin, J.; et al. Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium. Neurology 2017, 89, 88–100.
    18. Jellinger, K.A.; Korczyn, A.D. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? BMC Med. 2018, 16, 34.
    19. Lenka, A.; Pagonabarraga, J.; Pal, P.K.; Bejr-Kasem, H.; Kulisvesky, J. Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology 2019, 93, 259–266.
    20. Martínez-Horta, S.; Riba, J.; de Bobadilla, R.F.; Pagonabarraga, J.; Pascual-Sedano, B.; Antonijoan, R.M.; Romero, S.; Mañanas, M.À.; García-Sanchez, C.; Kulisevsky, J. Apathy in parkinson’s disease: Neurophysiological evidence of impaired incentive processing. J. Neurosci. 2014, 34, 5918–5926.
    21. Weintraub, D.; Mamikonyan, E. The Neuropsychiatry of Parkinson disease: A perfect storm. Am. J. Geriatr. Psychiatry 2019, 27, 998–1018.
    22. Aarsland, D.; Ballard, C.; Larsen, J.P.; McKeith, I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriatr. Psychiatry 2001, 16, 528–536.
    23. Marsh, L. Depression and Parkinson’s disease: Current knowledge. Curr. Neurol. Neurosci. Rep. 2013, 13, 409.
    24. Patterson, L.; Rushton, S.P.; Attems, J.; Thomas, A.J.; Morris, C.M. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathol. 2019, 29, 544–557.
    25. Ishihara, L.; Brayne, C. A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol. Scand. 2006, 113, 211–220.
    26. McKeith, I.; Cummings, J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005, 4, 735–742.
    27. Kuring, J.K.; Mathias, J.L.; Ward, L. Prevalence of depression, anxiety and PTSD in people with dementia: A systematic review and meta-analysis. Neuropsychol. Rev. 2018, 28, 393–416.
    28. Fritze, F.; Ehrt, U.; Hortobagyi, T.; Ballard, C.; Aarsland, D. Depressive symptoms in Alzheimer’s disease and Lewy body dementia: A one-year follow-up study. Dement. Geriatr. Cogn. Disord. 2011, 32, 143–149.
    29. Aarsland, D.; Brønnick, K.; Ehrt, U.; De Deyn, P.P.; Tekin, S.; Emre, M.; Cummings, J.L. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: Frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatry 2007, 78, 36–42.
    30. Borroni, B.; Agosti, C.; Padovani, A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): Frequency and relationship with disease severity and motor impairment. Arch. Gerontol. Geriatr. 2008, 46, 101–106.
    31. Breitve, M.H.; Brønnick, K.; Chwiszczuk, L.J.; Hynninen, M.J.; Aarsland, D.; Rongve, A. Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimer’s Res. Ther. 2018, 10.
    32. Fields, J.A. Cognitive and neuropsychiatric features in Parkinson’s and Lewy body dementias. Arch. Clin. Neuropsychol. 2017, 32, 786–801.
    33. Hynninen, M.J.; Breitve, M.H.; Rongve, A.; Aarsland, D.; Nordhus, I.H. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int. Psychogeriatr. 2012, 24, 1771–1778.
    34. Ffytche, D.H.; Creese, B.; Politis, M.; Chaudhuri, K.R.; Weintraub, D.; Ballard, C.; Aarsland, D. The psychosis spectrum in Parkinson disease. Nat. Rev. Neurol. 2017, 13, 81–95.
    35. Fénelon, G.; Mahieux, F.; Huon, R.; Ziégler, M. Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain 2000, 123, 733–745.
    36. Gomperts, S.N. Lewy body dementias: Dementia with lewy bodies and Parkinson disease dementia. Continuum 2016, 22, 435–463.
    37. State, D.; Events, S.L. Clinical features of auditory hallucinations in patients with dementia with lewy bodies: A soundtrack of visual hallucinations. J. Clin. Psychiatry 2014, 2012, 11–12.
    38. Pagonabarraga, J.; Martinez-Horta, S.; Fernández de Bobadilla, R.; Pérez, J.; Ribosa-Nogué, R.; Marín, J.; Pascual-Sedano, B.; García, C.; Gironell, A.; Kulisevsky, J. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov. Disord. 2016, 31, 45–52.
    39. Uchiyama, M.; Nishio, Y.; Yokoi, K.; Hirayama, K.; Imamura, T.; Shimomura, T.; Mori, E. Pareidolias: Complex visual illusions in dementia with Lewy bodies. Brain 2012, 135, 2458–2469.
    40. Uchiyama, M.; Nishio, Y.; Yokoi, K.; Hosokai, Y.; Takeda, A.; Mori, E. Pareidolia in Parkinson’s disease without dementia: A positron emission tomography study. Park. Relat. Disord. 2015, 21, 603–609.